An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer.

Trial Profile

An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2011 Actual end date changed from Nov 2010 to Mar 2011 as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top